Sichuan Biokin PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Sichuan Biokin PharmaceuticalLtd has been growing earnings at an average annual rate of 56.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 42.4% per year. Sichuan Biokin PharmaceuticalLtd's return on equity is 89.6%, and it has net margins of 65%.
Key information
56.4%
Earnings growth rate
55.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 42.4% |
| Return on equity | 89.6% |
| Net Margin | 65.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business
Nov 04
Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Earnings May Just Be The Starting Point
May 03Recent updates
Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business
Nov 04Getting In Cheap On Sichuan Biokin Pharmaceutical Co.,Ltd. (SHSE:688506) Is Unlikely
Oct 29Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Could Easily Take On More Debt
Aug 17Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Earnings May Just Be The Starting Point
May 03Revenue & Expenses Breakdown
How Sichuan Biokin PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,847 | 3,800 | 371 | 1,168 |
| 30 Jun 24 | 5,804 | 4,214 | 343 | 958 |
| 31 Mar 24 | 5,901 | 4,391 | 364 | 836 |
| 31 Dec 23 | 562 | -780 | 361 | 746 |
| 30 Sep 23 | 601 | -555 | 383 | 601 |
| 30 Jun 23 | 710 | -473 | 420 | 535 |
| 31 Mar 23 | 705 | -404 | 421 | 463 |
| 31 Dec 22 | 703 | -282 | 411 | 375 |
| 30 Sep 22 | 663 | -320 | 396 | 385 |
| 31 Dec 21 | 797 | -100 | 465 | 279 |
| 31 Dec 20 | 1,013 | 38 | 635 | 196 |
| 31 Dec 19 | 1,207 | 8 | 827 | 181 |
| 31 Dec 14 | 418 | 17 | 224 | 0 |
| 31 Dec 13 | 415 | 35 | 213 | 0 |
Quality Earnings: 688506 has high quality earnings.
Growing Profit Margin: 688506 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688506's earnings have grown significantly by 56.4% per year over the past 5 years.
Accelerating Growth: 688506 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 688506 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 688506's Return on Equity (89.6%) is considered outstanding.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:28 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sichuan Biokin Pharmaceutical Co.,Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shitong Han | Citic Securities Co., Ltd. |
| Wenxin Yu | Haitong International Research Limited |